Ⅳ期结直肠癌患者血清中VEGF水平的临床意义

Clinical significance of VEGF levels in serums of colorectal cancer patients at stage Ⅳ

目的探讨血清中血管内皮生长因子(VEGF)水平在Ⅳ期结直肠癌诊疗中的意义。方法应用酶联免疫吸附试验(ELISA)检测45例Ⅳ期结直肠癌患者血清VEGF水平,20例健康体检者作为正常对照。结果Ⅳ期患者姑息术后第7天血清中VEGF水平较术前显著降低(P<0.01)。能从bevacizumab治疗中获益的患者与未能从中获益的患者相比,其治疗前VEGF水平无统计学差异(P=0.554)。结论Ⅳ期结直肠癌患者血清中VEGF水平随肿瘤负荷减小而降低。Ⅳ期结直肠癌患者治疗前血清中VEGF水平的高低似乎不能预测其能否从含bevacizumab的治疗方案中获益。

Objective To investigate the clinical significance of vascular endothelial growth factor （VEGF） levels in serums of colorectal cancer patients at stage Ⅳ. Method Using enzyme linked immunosorbent assay （ELISA） to detect the VEGF levels in serums of 45 colorectal cancer patients at stage Ⅳ, and 20 healthy served as normal control. Results The mean concentration of VEGF in 45 colorectal cancer patients at the 7 day after operation were significantly lower than that before operation （P〈0.01）. The mean concentration of VEGF in the patients who benefit from bevacizumab showed no statistical difference from the levels of who did not benefit （P=-0.554）. Conclusion The VEGF levels in colorectal patients at stage Ⅳ are lowed as the load of tumor decrease. The circulating levels of VEGF seem not predict the response to bevacizumab in colorectal cancer patients at stage Ⅳ.